Table 1 Baseline characteristics and intraoperative data of living donor liver transplantation recipients and donors.
Total (N = 1833) | Weight gain <3% (n = 1391) | Weight gain ≥3% (n = 442) | P-value | |
|---|---|---|---|---|
Demographic | ||||
Age (years) | 53.0 (49.0–57.0) | 53.0 (48.0–57.0) | 54.0 (49.0–58.0) | 0.004 |
Sex, male | 1383 (75.5%) | 1081 (77.7%) | 302 (68.3%) | <0.001 |
Body mass index (kg/m2) | 23.8 ± 3.3 | 24.0 ± 3.2 | 23.0 ± 3.2 | <0.001 |
Diabetes mellitus | 385 (21.0%) | 268 (19.3%) | 117 (26.5%) | 0.002 |
Hypertension | 236 (12.9%) | 173 (12.4%) | 63 (14.3%) | 0.362 |
Coronary arterial disease | 65 (3.5%) | 44 (3.2%) | 21 (4.8%) | 0.154 |
Liver disease | ||||
Fulminant hepatic failure | 78 (4.3%) | 57 (4.1%) | 21 (4.8%) | 0.647 |
Model for end-stage liver disease score | 12.0 (9.0–18.0) | 12.0 (9.0–18.0) | 12.0 (9.0–18.0) | 0.951 |
Hepatic encephalopathy | 251 (13.7%) | 169 (12.1%) | 82 (18.6%) | 0.001 |
Ascites | 554 (30.2%) | 466 (33.5%) | 88 (19.9%) | <0.001 |
Spontaneous bacterial peritonitis | 99 (5.4%) | 80 (5.8%) | 19 (4.3%) | 0.291 |
Combined hepatocellular carcinoma | 927 (50.6%) | 685 (49.2%) | 242 (54.8%) | 0.050 |
Laboratory data | ||||
Haemoglobin (g/dL) | 11.0 ± 2.2 | 11.0 ± 2.2 | 11.1 ± 2.1 | 0.553 |
Prothrombin time (INR) | 1.4 (1.2–1.7) | 1.4 (1.2–1.7) | 1.4 (1.2–1.6) | 0.923 |
Total bilirubin (mg/dL) | 1.9 (1.1–4.5) | 1.9 (1.1–4.5) | 1.9 (1.2–4.2) | 0.717 |
Creatinine (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.974 |
Brain natriuretic peptide (pg/mL) | 40.0 (19.0–84.0) | 42.0 (20.0–85.0) | 34.0 (16.0–83.0) | 0.005 |
Donor variables | ||||
Donor age (years) | 26.0 (21.0–32.0) | 26.0 (21.0–32.0) | 27.0 (23.0–32.0) | 0.001 |
Donor sex, male | 1319 (72.0%) | 1021 (73.4%) | 298 (67.4%) | 0.017 |
Donor body mass index (kg/m2) | 22.9 ± 2.9 | 22.9 ± 2.9 | 23.1 ± 2.9 | 0.201 |
Total fatty change (%) | 1.0 (0.0–5.0) | 1.0 (0.0–5.0) | 2.0 (0.0–5.0) | 0.199 |
Macro fatty change (%) | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | 0.295 |
Intraoperative data | ||||
Graft-to-recipient weight ratio | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.2 ± 0.3 | 0.003 |
Postreperfusion syndrome | 714 (39.0%) | 542 (39.0%) | 172 (38.9%) | 1.000 |
Cold ischaemic time (min) | 81.0 (66.0–98.0) | 81.0 (67.0–98.0) | 82.0 (65.0–100.0) | 0.872 |
Warm ischaemic time (min) | 40.0 (33.0–50.0) | 40.0 (32.0–48.0) | 43.0 (35.0–57.0) | <0.001 |
Operation time (min) | 840.0 (760.0–930.0) | 822.0 (750.0–905.0) | 886.5 (805.0–975.0) | <0.001 |
Fluid balance | ||||
Crystalloid (L) | 6.3 (5.0–7.9) | 6.0 (4.8–7.2) | 7.7 (6.0–10.3) | <0.001 |
Albumin (L) | 3.0 (2.3–4.0) | 3.0 (2.0–3.8) | 3.3 (2.5–5.0) | <0.001 |
Packed red blood cell transfusion (units) | 6.0 (2.0–12.0) | 6.0 (2.0–11.0) | 9.0 (4.0–18.0) | <0.001 |
Fresh frozen plasma transfusion (units) | 7.0 (2.0–14.0) | 6.0 (2.0–12.0) | 10.0 (5.0–20.0) | <0.001 |
Urine output (L) | 1.5 (1.0–2.0) | 1.4 (1.0–1.9) | 1.6 (1.2–2.4) | <0.001 |
Epinephrine use | 687 (37.5%) | 521 (37.5%) | 166 (37.6%) | 1.000 |
Vasopressor use | 1083 (59.1%) | 848 (61.0%) | 235 (53.2%) | 0.004 |
